Roughly 1 in 5 patients taking AstraZeneca’s blood thinner Brilinta during trials stopped using the drug because of side effects, according to new research.
Bleeding and shortness of breath were among the adverse effects found in the Pegasus-TMI 54 study, which evaluated the reasons patients discontinued Brilinta, also known by its chemical name, ticagrelor. The research data was presented during the Late Breaking Clinical Trial session at the 2015 American Heart Association Scientific Sessions.
Help employers find you! Check out all the jobs and post your resume.
